

THORATEC CORP  
Form 10-Q  
August 11, 2003

**Table of Contents**

---

---

**U.S. SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 10-Q**

(Mark one)

**Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934**

**For the quarterly period ended June 28, 2003**

**or**

**Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934**

**for the transition period from to**

**COMMISSION FILE NUMBER: 1-8145**

**THORATEC CORPORATION**

**(Exact name of registrant as specified in its charter)**

**California**  
**(State or Other Jurisdiction of**  
**Incorporation or Organization)**

**94-2340464**  
**(I.R.S. Employer Identification No.)**

**6035 Stoneridge Drive, Pleasanton, California**  
**(Address of Principal Executive Offices)**

**94588**  
**(Zip Code)**

**Registrant's telephone number, including area code: (925) 847-8600**

*Indicate by check mark whether the registrant:* (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

As of August 5, 2003 registrant 55,640,106 shares of common stock outstanding.

---

---

---

**TABLE OF CONTENTS**

**PART I. FINANCIAL INFORMATION**

**ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE OF MARKET RISK**

**ITEM 4. CONTROLS AND PROCEDURES**

**PART II. OTHER INFORMATION**

**ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY SHAREHOLDERS**

**ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K**

**SIGNATURES**

**Exhibit Index**

**Exhibit 31.1**

**Exhibit 32.1**

---

**Table of Contents**

**THORATEC CORPORATION AND SUBSIDIARIES  
TABLE OF CONTENTS**

Part I. Financial Information
Item 1. Condensed Consolidated Financial Statements (unaudited)
Condensed Consolidated Balance Sheets as of June 28, 2003 and December 28, 2002
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 28, 2003 and June 29, 2002
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 28, 2003 and June 29, 2002
Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 28, 2003 and June 29, 2002
Notes to Condensed Consolidated Financial Statements
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosure of Market Risk
Item 4. Controls and Procedures
Part II. Other Information
Item 4. Submission of Matters to a Vote of Security Shareholders
Item 6. Exhibits and Reports on Form 8-K
Signatures
Exhibits

**Table of Contents****PART I. FINANCIAL INFORMATION****ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****THORATEC CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS****(unaudited)  
(in thousands)**

	<b>June 28, 2003</b>	<b>December 28, 2002</b>
	<u>                    </u>	<u>                    </u>
<b>Assets</b>		
<b>Current Assets:</b>		
Cash and cash equivalents	\$ 57,545	\$ 42,044
Short-term available-for-sale investments		3,439
Receivables, net of allowances of \$221 in 2003 and \$238 in 2002	26,433	27,593
Inventories	37,409	38,835
Deferred tax asset	11,546	12,182
Prepaid expenses and other assets	2,772	2,517
	<u>                    </u>	<u>                    </u>
<b>Total Current Assets</b>	<b>135,705</b>	<b>126,610</b>
	<u>                    </u>	<u>                    </u>
Property, plant and equipment, net	24,808	24,715
Long-term available-for-sale investments	31,731	30,051
Goodwill	96,492	96,492
Purchased intangible assets, net	178,235	184,282
Long-term deferred tax asset	3,242	5,244
Other assets	1,056	1,038
	<u>                    </u>	<u>                    </u>
<b>Total Assets</b>	<b>\$471,269</b>	<b>\$468,432</b>
	<u>                    </u>	<u>                    </u>
<b>Liabilities and Shareholders' Equity</b>		
<b>Current Liabilities:</b>		
Accounts payable	\$ 5,207	\$ 6,319
Accrued compensation	5,939	6,372
Accrued merger, restructuring and other		1,208
Estimated liabilities for warranty, legal and other	1,411	1,304
Other accrued liabilities	3,193	3,435
	<u>                    </u>	<u>                    </u>
<b>Total Current Liabilities</b>	<b>15,750</b>	<b>18,638</b>
	<u>                    </u>	<u>                    </u>
Long-term deferred tax liability and other	73,001	75,454
	<u>                    </u>	<u>                    </u>
<b>Total Liabilities</b>	<b>88,751</b>	<b>94,092</b>
	<u>                    </u>	<u>                    </u>
<b>Shareholders' Equity:</b>		
Common shares; 100,000 authorized; issued and outstanding 55,570 in 2003 and 55,037 in 2002	415,330	410,266

Edgar Filing: THORATEC CORP - Form 10-Q

Deferred compensation	(3,136)	(3,735)
Accumulated deficit	(29,972)	(32,412)
Accumulated other comprehensive income:		
Cumulative foreign currency translation adjustments	147	91
Unrealized gain on investment	149	130
	<u>          </u>	<u>          </u>
Total accumulated other comprehensive income	296	221
	<u>          </u>	<u>          </u>
Total Shareholders' Equity	382,518	374,340
	<u>          </u>	<u>          </u>
Total Liabilities and Shareholders' Equity	\$471,269	\$468,432
	<u>          </u>	<u>          </u>

See notes to condensed consolidated financial statements.

**Table of Contents****THORATEC CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(unaudited)  
(in thousands, except per share data)

	Three Months Ended		Six Months Ended	
	June 28, 2003	June 29, 2002	June 28, 2003	June 29, 2002
Product sales	\$36,156	\$31,034	\$72,218	\$60,673
Cost of product sales	14,651	13,281	29,542	26,445
Gross profit	21,505	17,753	42,676	34,228
Operating expenses:				
Selling, general and administrative	11,169	9,847	21,229	18,566
Research and development	6,279	6,083	12,539	12,985
Amortization of purchased intangible assets	3,096	3,096	6,192	6,192
Merger, restructuring and other costs	(67)	506	(124)	827
Total operating expenses	20,477	19,532	39,836	38,570
Income (loss) from operations	1,028	(1,779)	2,840	(4,342)
Interest and other income net	649	854	1,160	485
Income (loss) before income tax expense (benefit)	1,677	(925)	4,000	(3,857)
Income tax expense (benefit)	654	(369)	1,560	(1,543)
Net income (loss)	\$ 1,023	\$ (556)	\$ 2,440	\$ (2,314)
Net income (loss) per share, basic and diluted	\$ 0.02	\$ (0.01)	\$ 0.04	\$ (0.04)
Shares used to compute net income (loss) per share:				
Basic	55,394	56,799	55,226	56,725
Diluted	56,891	56,799	56,240	56,725

See notes to condensed consolidated financial statements.

**Table of Contents****THORATEC CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**(unaudited)  
(in thousands)

	Six Months Ended	
	June 28, 2003	June 29, 2002
<b>Cash flows from operating activities:</b>		
Net income (loss)	\$ 2,440	\$ (2,314)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization	9,234	8,365
Amortization of deferred compensation	599	559
Non-cash compensation	4	152
Change in net deferred tax liability	1,140	(1,261)
Changes in assets and liabilities:		
Receivables	1,225	3,639
Inventories	1,499	(7,052)
Prepaid expenses and other assets	(274)	(106)
Accounts payable and other liabilities	(3,022)	(2,936)
Net cash provided by (used in) operating activities	<u>12,845</u>	<u>(954)</u>
<b>Cash flows from investing activities:</b>		
Purchases of available-for-sale investments	(4,439)	
Sales of available-for-sale investments	5,709	
Reclassification from restricted cash and cash equivalents		45,884
Purchases of property, plant and equipment	(2,831)	(3,666)
Net cash provided by (used in) investing activities	<u>(1,561)</u>	<u>42,218</u>
<b>Cash flows from financing activities:</b>		
Proceeds from stock option exercises	3,571	643
Proceeds from common stock offering		15,446
Proceeds from common stock issued under ESPP	578	
Repayment of convertible debentures		(54,838)
Repurchase of common stock		(6,033)
Net cash provided by (used in) financing activities	<u>4,149</u>	<u>(44,782)</u>
Effect of exchange rate changes on cash	68	48
Net increase (decrease) in cash and cash equivalents	15,501	(3,470)
Cash and cash equivalents at beginning of period	42,044	91,726
Cash and cash equivalents at end of period	<u>\$ 57,545</u>	<u>\$ 88,256</u>
<b>Supplemental Cash Flow Disclosure:</b>		
Cash paid for taxes	\$ 722	\$ 180
Cash paid for interest		839



Edgar Filing: THORATEC CORP - Form 10-Q

**Supplemental Disclosure of Non-Cash Investing and Financing Activities:**

Reclassification of assembled workforce, net of taxes	\$	\$ 1,334
Tax benefit related to stock option exercises	911	147

See notes to condensed consolidated financial statements.

**Table of Contents****THORATEC CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)****(unaudited)**  
**(in thousands)**

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 28, 2003</b>	<b>June 29, 2002</b>	<b>June 28, 2003</b>	<b>June 29, 2002</b>
Net income (loss)	\$ 1,023	\$ (556)	\$ 2,440	\$ (2,314)
Other net comprehensive income (loss):				
Unrealized gain (loss) on investments	(2)		19	
Foreign currency translation adjustments	84	60	56	50
Comprehensive income (loss)	\$ 1,105	\$ (496)	\$ 2,515	\$ (2,264)

See notes to condensed consolidated financial statements.

**Table of Contents**

**THORATEC CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(Unaudited)**

**1. Basis of Presentation**

The interim condensed consolidated financial statements of Thoratec Corporation, referred to as we, our, Thoratec, or the Company have been prepared and presented in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission, or the SEC, without audit and, in our opinion, reflect all adjustments necessary (consisting only of normal recurring adjustments) to present fairly our financial position at June 28, 2003 and December 28, 2002, our results of operations for the three-month and six-month periods ended June 28, 2003 and June 29, 2002 and cash flows for the six-month periods ended June 28, 2003 and June 29, 2002. Certain information and footnote disclosures normally included in our annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The accompanying financial statements should be read in conjunction with our fiscal 2002 consolidated financial statements filed with the SEC in our Annual Report on Form 10-K. The operating results for any interim period are not necessarily indicative of the results that may be expected for any future period.

The preparation of our condensed consolidated financial statements included herein necessarily requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the consolidated balance sheet dates and the reported amounts of revenues and expenses for the periods presented.

We have made certain reclassifications of 2002 amounts to conform to the current presentation.

**2. Merger of Thoratec and TCA**

Our merger with Thermo Cardiosystems Inc., or TCA, was completed on February 14, 2001, which we refer to as the Merger. The Merger was accounted for under the purchase method of accounting and was treated as a reverse acquisition because the shareholders of TCA owned the majority of our common stock after the Merger. TCA was considered the acquiror for accounting and financial reporting purposes. Due to the reverse acquisition, Thoratec's assets and liabilities were recorded based upon their estimated fair market values at the date of acquisition.

As a result of the Merger, \$76,858,000 relating to in-process research and development, or IPR&D, was expensed in the first quarter of 2001. The one-time write-off of IPR&D related to four technology projects that were in development, had not reached technological feasibility, had no alternative future use and for which successful development was uncertain. One of the projects was completed in 2002. There have been no significant developments subsequent to the Merger related to the current status of any of the three remaining IPR&D projects that would result in material changes to the assumptions or resulting valuation performed at the time of the Merger. Development of IPR&D projects continues and while the timing of completion of these projects may vary due to the highly regulated and technical nature of our products, current estimates remain materially consistent with our initial estimates.

**3. New Accounting Pronouncements**

In June 2001, the Financial Accounting Standards Board, or FASB, issued Statement of Financial Accounting Standards, or SFAS, No. 143, Accounting for Asset Retirement Obligations. SFAS No. 143 addresses financial accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs, including legal obligations. The adoption of SFAS No. 143 as of the beginning of fiscal year 2003 did not have any impact on our financial position, results of operations or cash flows.

In April 2002, the FASB issued SFAS No. 145, (Rescission of FASB Statements 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections) which, among other things, changed the presentation of gains and losses on the extinguishment of debt. Any gain or loss on extinguishment of debt that does not meet the criteria in Accounting Principle Board, or APB, Opinion No. 30, Reporting the Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions, shall be included in operating earnings and not presented separately as an extraordinary item. We adopted SFAS No. 145 at the beginning of fiscal year 2003. Upon adoption, we reclassified the extraordinary loss on extinguishment of debt incurred in the first quarter of 2002 of \$515,000 to interest and other income (expense)-net.

**Table of Contents**

In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities, which addresses accounting for restructuring and similar costs. SFAS No. 146 supersedes previous accounting guidance, principally Emerging Issues Task Force Issue, or EITF, No. 94-3 Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit on Activity (Including Certain Costs Incurred in a Restructuring). The Company will adopt the provisions of SFAS No. 146 for any restructuring activities initiated after December 31, 2002. SFAS No. 146 may affect the timing of recognizing future restructuring costs as well as the amounts recognized.

In November 2002, the FASB issued Financial Interpretation, or FIN, No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others. FIN No. 45 requires a liability to be recognized at the time a company issues a guarantee for the fair value of the obligations assumed under certain guarantee agreements. Additional disclosures about guarantee agreements are also required in the interim and annual financial statements, including a roll forward of the entity's product warranty liabilities. The disclosure provisions of FIN No. 45 were effective for us as of fiscal year end 2002. The provisions for initial recognition and measurement of guarantee agreements are effective on a prospective basis for guarantees that are issued or modified after December 28, 2002. We do not expect that the recognition provisions of FIN No. 45 will have a material impact upon our consolidated financial statements.

In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure. SFAS No. 148 amends SFAS No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements of the method of accounting for stock-based employee compensation and the effect of the method used on reported results. SFAS No. 148 is effective for fiscal years beginning after December 15, 2002. We adopted the disclosure provisions of SFAS No. 148 at the beginning of fiscal 2003. Currently we are evaluating the impact of the adoption of the use of the fair value based method of accounting for stock-based financial position, results of operations and cash flows.

We account for stock-based compensation to employees using the intrinsic value method in accordance with Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees. Accordingly, no accounting recognition is given to stock options granted at fair market value until they are exercised. Upon exercise, net proceeds, including tax benefits realized, are recorded in common stock. Similarly, no accounting recognition is given to our recently implemented employee stock purchase plan until a purchase occurs. Upon purchase, net proceeds are recorded in common stock. Under fair value recognition provisions of SFAS No. 123, the fair value of each option granted as a stock option or as an option to purchase shares under the employee stock purchase plan is estimated using the Black-Scholes option pricing model. If compensation cost for our stock-based plans had been determined based on the fair value at the grant dates for awards under those plans, consistent with the method of SFAS No. 123, our reported net income (loss) would have been adversely affected, as shown in the following table (in thousands, except per share data):

	Three Months Ended		Six Months Ended	
	June 28, 2003	June 29, 2002	June 28, 2003	June 29, 2002
Net income (loss):				
As reported	\$ 1,023	\$ (556)	\$ 2,440	\$ (2,314)
Add: Stock-based compensation expense included in reported net income, net of related tax effects		55	4	93
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects	(1,670)	(2,459)	(3,448)	(4,528)
Pro forma	\$ (647)	\$ (2,960)	\$ (1,004)	\$ (6,749)
Basic and diluted earnings (loss) per share:				
As reported	\$ 0.02	\$ (0.01)	\$ 0.04	\$ (0.04)
Pro forma	\$ (0.01)	\$ (0.05)	\$ (0.04)	\$ (0.12)

**Table of Contents**

In April 2003, the FASB issued SFAS No. 149, *Amendment of Statement 133 on Derivative Instruments and Hedging Activities*. This statement amends and clarifies financial accounting and reporting for derivative instruments, including certain derivative instruments embedded in other contracts (collectively referred to as derivatives) and for hedging activities under FASB Statement No. 133, *Accounting for Derivative Instruments and Hedging Activities*. This statement is effective for contracts entered into or modified after June 30, 2003. The adoption of this statement is not expected to have an impact on Thoratec's financial position, results of operations or cash flows.

In May 2003, the FASB issued SFAS No. 150, *Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity*. This statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. This statement is effective for financial instruments entered into or modified after May 31, 2003 and for hedging relationships designated after June 30, 2003. The adoption of this statement is not expected to have an impact on Thoratec's financial position, results of operations or cash flows.

**4. Inventories**

Inventories consist of the following (in thousands):

	As of	
	June 28, 2003	December 28, 2002
Finished goods	\$20,830	\$22,119
Work in process	5,544	6,645
Raw materials	11,035	10,071
	<u>          </u>	<u>          </u>
Total	\$37,409	\$38,835
	<u>          </u>	<u>          </u>

**5. Property, Plant and Equipment**

Property, plant, and equipment consist of the following (in thousands):

	As of	
	June 28, 2003	December 28, 2002
Property, plant and equipment, at cost	\$ 51,510	\$ 49,355
Less accumulated depreciation	(26,702)	(24,640)
	<u>          </u>	<u>          </u>
Total	\$ 24,808	\$ 24,715
	<u>          </u>	<u>          </u>

**Table of Contents****6. Goodwill and Other Intangible Assets**

The changes in the carrying amount of goodwill, which is only attributable to our Cardiovascular business segment, for the six-month periods ended June 28, 2003 and June 29, 2002 were as follows (in thousands):

	Six Months Ended	
	June 28, 2003	June 29, 2002
Beginning balance	\$96,492	\$95,209
Reclassification of assembled workforce, net of taxes		1,334
Adjustment to reflect resolution of pre-merger contingency		(51)
Ending balance	\$96,492	\$96,492

The components of identifiable intangible assets, consisting primarily of patents and trademarks, core technology and developed technology, which are included in purchased intangible assets on the consolidated balance sheets, were as follows (in thousands):

	As of June 28, 2003		
	Gross Carrying	Accumulated	Net Carrying
	Amount	Amortization	
Developed Technology	\$132,301	\$(15,710)	\$ 116,591
Core Technology	37,181	(4,415)	32,766
Patents and Trademarks	37,478	(8,600)	28,878
Total Purchased Intangible Assets	\$206,960	\$(28,725)	\$ 178,235

	As of December 28, 2002		
	Gross Carrying	Accumulated	Net Carrying
	Amount	Amortization	
Developed Technology	\$132,301	\$(12,403)	\$ 119,898
Core Technology	37,181	(3,486)	33,695
Patents and Trademarks	37,478	(6,789)	30,689
Total Purchased Intangible Assets	\$206,960	\$(22,678)	\$ 184,282

As of the beginning of fiscal 2002, the purchased intangible asset associated with the assembled workforce in the amount of \$1,334,000, net of accumulated amortization of \$381,000 and taxes of \$897,000, was reclassified to goodwill.

Amortization expense related to identifiable intangible assets for the three month and six month periods ended June 28, 2003 and June 29, 2002 was \$3,096,000, \$6,192,000, \$3,096,000 and \$6,192,000, respectively. For the three and six months ended June 28, 2003 and June 20, 2002, purchased intangible assets amortization expense also included \$72,000, \$144,000, \$72,000 and \$144,000, respectively, of amortization of

## Edgar Filing: THORATEC CORP - Form 10-Q

deferred compensation recorded at the time of the Merger related to the valuation of stock options. Amortization expense is expected to be approximately \$12,300,000 for each of the next five years. The purchased intangible assets have estimated useful lives of eight to twenty years.

### **7. Common Stock**

On May 30, 2003, our 1996 Nonemployee Directors Stock Option Plan ( Directors Option Plan ) and our 1997 Stock Option Plan ( 1997 SOP ) were amended by approval of a vote of our Company's shareholders. These amendments increased the number of shares of our common stock reserved for issuance of options granted under the Directors Option Plan and the 1997 SOP by 200,000 and 4,500,000, respectively. These increases assist us in attracting and retaining employees and non-employee directors.

**Table of Contents****8. Merger, Restructuring and Other Costs**

Merger, restructuring and other costs were recorded in the condensed consolidated statements of operations as follows (in thousands):

	Three Months Ended		Six Months Ended	
	June 28, 2003	June 29, 2002	June 28, 2003	June 29, 2002
Merger	\$	\$ 152	\$	\$ 289
Restructuring	(61)	354	(118)	538
Other	(6)		(6)	
Total	\$(67)	\$506	\$(124)	\$827

**Merger Costs**

All merger activities and related expenses were completed in the third quarter of 2002. Merger costs recorded during the three and six months ended June 29, 2002 consisted of executive waiver agreement expenses. In accordance with the executive waiver agreements, payments to the executives occurred at the one-year anniversary of the Merger, although the executives continued to be restricted from exercising some of their options and selling the related stock for an additional six months following the one-year anniversary date. The total expense related to the waiver agreements of \$811,000 was amortized over the 18-month waiver period. As of June 29, 2002, the ending balance of accrued merger costs was reclassified to prepaid expenses and other in the accompanying condensed consolidated balance sheet.

The following table reflects the activity in accrued merger costs for the three-month and six-month periods ended June 29, 2002 (in thousands):

	Three Months Ended June 29, 2002	Six Months Ended June 29, 2002
Beginning balance	\$ (198)	\$ 472
Add:		
Accruals pursuant to executive waiver agreements	135	270
Accruals of other merger costs	17	19
Less:		
Payments pursuant to executive waiver agreements		(810)
Payments of other merger costs	(17)	(14)
Ending balance	\$ (63)	\$ (63)



**Table of Contents****Restructuring Costs**

All restructuring activities and related expenses were completed in the second quarter of 2003. From the inception of our plan to consolidate all of our ventricular assist device, or VAD, manufacturing operations, which we call the Restructuring Plan, through June 28, 2003, we recorded \$1,495,000 of restructuring charges in accordance with EITF Issue No. 94-3, and Staff Accounting Bulletin No. 100, Restructuring and Impairment Charges. These charges represented estimated employee severance costs and stock option acceleration charges. Total severance payments under the Restructuring Plan were \$1,297,000 to 78 employees. The following is a summary of our accrued restructuring costs activity for the three-month and six-month periods ended June 28, 2003 and June 29, 2002 (in thousands):

	Three Months Ended		Six Months Ended	
	June 28, 2003	June 29, 2002	June 28, 2003	June 29, 2002
<b>Accrued Restructuring Costs:</b>				
Beginning balance	\$ 97	\$ 881	\$ 679	\$ 863
Employee severance accrual		242		386
Reduction of severance accrual	(61)		(122)	
Payments of employee severance	(36)	(284)	(557)	(410)
Ending balance	\$	\$ 839	\$	\$ 839

For the three months and six months ended June 28, 2003 and June 29, 2002, in addition to the employee severance costs, estimated restructuring costs included expense related to the acceleration of stock options granted to employees who were terminated under the Restructuring Plan. Stock option acceleration expense recorded in the three-month and six-month periods ending June 28, 2003 and June 29, 2002, were nil, \$4,000, \$112,000 and \$152,000, respectively.

**Other Costs**

Other costs of \$529,000 were accrued in the fourth quarter of 2002 related to the termination of a European distribution agreement. In the first quarter of 2003, \$523,000 of this amount was paid. The remaining \$6,000 of the original accrual was reversed from expense in the second quarter of 2003 as an adjustment to estimated settlement costs.

**9. Income Taxes**

Our effective tax provision rate was 39% for the three-month and six-month periods ended June 28, 2003. For both the three and six-months periods ended June 29, 2002, our effective tax benefit rate was 40%. The effective tax provision rate for the first quarter of 2003 and the effective tax benefit rate for the first quarter of 2002 both differed from the statutory federal income tax rate primarily due to the impact of state taxes.

At June 28, 2003 and December 28, 2002, we reported a net deferred tax liability of approximately \$56,885,000 and \$56,655,000, respectively, comprised principally of temporary differences between the financial statement and income tax bases of intangible assets.

**10. Net Income (Loss) Per Share**

Basic and diluted net income (loss) per share were calculated as follows (in thousands, except per share amounts):

Three Months Ended		Six Months Ended	
June 28, 2003	June 29, 2002	June 28, 2003	June 29, 2002

Edgar Filing: THORATEC CORP - Form 10-Q

Net income (loss)	\$ 1,023	\$ (556)	\$ 2,440	\$ (2,314)
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
Weighted average number of common shares-basic	55,394	56,799	55,226	56,725
Dilutive effect of employee stock plans	1,497		1,014	
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
Weighted average number of common shares-diluted	56,891	56,799	56,240	56,725
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
Net income (loss) per common share-basic and diluted	\$ 0.02	\$ (0.01)	\$ 0.04	\$ (0.04)
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>

**Table of Contents**

Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Of the options to purchase shares of common stock outstanding as of June 28, 2003, options covering 3,512,000 shares and 3,979,000 shares of common stock were not included in the computation of the diluted income (loss) per share for the three-month and six-month periods ending June 28, 2003, respectively, as their inclusion would be antidilutive. Of the options to purchase shares of common stock outstanding as of June 29, 2002, all shares were excluded from the computation of diluted net loss per share for both the three-month and the six-month periods as their inclusion would be antidilutive due to our net losses during these periods.

**11. Business Segment and Geographical Data**

We organize and manage our business by functional operating entities. Our functional entities operate in two segments: (1) Cardiovascular and (2) ITC. The Cardiovascular segment develops, manufactures and markets proprietary medical devices used for circulatory support and vascular graft applications. The ITC segment develops, manufactures and markets near-patient, whole-blood coagulation testing equipment and related disposables, as well as premium quality, single-use skin incision devices.

Business Segments (in thousands):

	Three Months Ended		Six Months Ended	
	June 28, 2003	June 29, 2002	June 28, 2003	June 29, 2002
<b>Product sales:</b>				
Cardiovascular	\$23,559	\$19,829	\$47,467	\$38,520
ITC	12,597	11,205	24,751	22,153
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
Total product sales	\$36,156	\$31,034	\$72,218	\$60,673
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
<b>Income (loss) before income taxes:</b>				
Cardiovascular	\$ 3,453	\$ 1,747	\$ 7,242	\$ 1,875
ITC	2,138	2,149	4,487	4,381
Corporate (a)	(1,534)	(2,073)	(2,821)	(3,579)
<b>Purchase accounting entries:</b>				
Amortization of goodwill and purchased intangibles (b)	(3,096)	(3,096)	(6,192)	(6,192)
Merger, restructuring and other costs (b)	67	(506)	124	(827)
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
Total operating income (loss)	1,028	(1,779)	2,840	(4,342)
Interest and other income, net	649	854	1,160	485
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
Income (loss) before income taxes	\$ 1,677	\$ (925)	\$ 4,000	\$ (3,857)
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>

(a) Represents primarily general and administrative expenses not specifically identified to any particular business segment.

(b) Related to the Cardiovascular segment.

Geographic Areas (in thousands):

	Three Months Ended		Six Months Ended	
	June 28, 2003	June 29, 2002	June 28, 2003	June 29, 2002
<b>Product sales:</b>				
Domestic	\$30,247	\$25,324	\$60,251	\$50,075

Edgar Filing: THORATEC CORP - Form 10-Q

Europe	4,046	3,263	8,237	6,544
All other international	1,863	2,447	3,730	4,054
<b>Total international</b>	<b>5,909</b>	<b>5,710</b>	<b>11,967</b>	<b>10,598</b>
<b>Total</b>	<b>\$36,156</b>	<b>\$31,034</b>	<b>\$72,218</b>	<b>\$60,673</b>

**12. Legal Matters**

In May 2003, a patent infringement complaint was filed against us by Bodycote Materials Testing Canada, Inc. and David C. MacGregor, M.D. We have not yet responded to the complaint. We are currently evaluating the claims set forth in the complaint as well as the validity of the plaintiffs' underlying patents. As a result, an estimate of any potential loss or range of losses cannot be made at this time. However, we intend to investigate the claims thoroughly and take all necessary steps to appropriately defend ourselves against the claims set forth in the complaint.

**Table of Contents**

**13. Subsequent Events**

On July 17, 2003, we entered into an asset purchase agreement to acquire the Immediate Response Mobile Analysis, or IRMA, point-of-care blood analysis system product line from Diametrics Medical, Inc. ( Diametrics ). We will pay approximately \$5,000,000 in cash and assume certain trade payables related to the assets. The acquisition is subject to a number of conditions, including approval from Diametrics's shareholders, and is expected to close in the second half of 2003.

**Table of Contents**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Forward-Looking Statements**

*This Form 10-Q may contain statements that we believe are, or may be considered to be, forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally can be identified by use of statements that include phrases such as believe, expect, anticipate, intend, plan, foresee, may, hope, wish, potential, continue or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals also are forward-looking statements. All of these forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statement. The principal risk factors that could cause actual performance and future actions to differ materially from the forward-looking statements include, but are not limited to, the results of clinical trials, governmental regulatory approval processes, plans to develop and market new products, market acceptance of new products, announcements by our competitors, an intensely competitive market, the ability to improve financial performance, and other factors identified in our Annual Report on Form 10-K for 2002 which we filed with the Securities and Exchange Commission, or the SEC. Readers are urged to consider these factors carefully in evaluating the forward-looking statements. The forward-looking statements included in this Form 10-Q are made only as of the date of this report and we undertake no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*

*The following presentation of management's discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements included in this Form 10-Q, and our Annual Report on Form 10-K for 2002 filed with the SEC.*

**Overview**

We are a leading manufacturer of circulatory support products for use by patients with congestive heart failure, or CHF. According to the American Heart Association, 4.9 million patients in the United States suffer from CHF and an additional 550,000 patients are diagnosed with this disease annually. We were the first company to receive U.S. Food and Drug Administration, or FDA, approval to commercially market a ventricular assist device, or VAD, to treat patients with late-stage heart failure, which comprises approximately 5% to 10% of the CHF patient population. Our VADs are used primarily by these CHF patients to perform some or all of the pumping function of the heart and we currently offer the widest range of products to serve this market. We believe that our long-standing reputation for quality and innovation and our excellent relationships with leading cardiovascular surgeons worldwide position us to capture growth opportunities in the expanding congestive heart failure market. We also develop and sell products that are used by physicians and hospitals for vascular and diagnostic applications that include vascular grafts, blood coagulation testing and skin incision devices. We conduct business both domestically and internationally.

**The Merger with Thermo Cardiosystems**

The Merger of Thoratec with Thermo Cardiosystems, Inc., or TCA, was completed on February 14, 2001. We issued new shares of our common stock to the shareholders of TCA in exchange for all the outstanding common stock of TCA at an exchange ratio of 0.835 shares of Thoratec stock for each share of TCA stock. The Merger was accounted for as a reverse acquisition because former shareholders of TCA owned a majority of our outstanding stock subsequent to the Merger. For accounting purposes, TCA is deemed to have acquired Thoratec.

**Restructuring Plan**

All restructuring activities and related expenses were completed in the second quarter of 2003. From the inception of our plan to consolidate all of our VAD manufacturing operations, which we call the Restructuring Plan, through June 28, 2003, we recorded \$1.5 million of restructuring charges in accordance with Emerging Issues Task Force, or EITF, Issue No. 94-3, and Staff Accounting Bulletin No. 100,

Restructuring and Impairment Charges. These charges represented estimated employee severance costs and stock option acceleration charges. Total severance payments under the Restructuring Plan were \$1.3 million to 78 employees.

## **Table of Contents**

### **Other Recent Events**

In May 2003, a patent infringement claim was filed against us by Bodycote Materials Testing Canada, Inc. and David C. MacGregor, M.D. We have not yet responded to the complaint. We are currently evaluating the claims set forth in the complaint as well as the validity of the plaintiffs' underlying patents. As a result, an estimate of any potential loss or range of loss cannot be made at this time. We intend to vigorously defend ourselves against the claims set forth in the complaint.

On July 17, 2003, we entered into an asset purchase agreement to acquire the IRMA (Immediate Response Mobile Analysis) point-of-care blood analysis system product line from Diametrics Medical, Inc. (Diametrics). We will pay approximately \$5,000,000 and assume certain trade payables related to the assets. The acquisition is subject to a number of conditions, including approval from Diametrics's shareholders, and is expected to close in the second half of 2003.

On July 28, 2003, we received CE Mark certification, which provides us with approval to market our Thoratec Implantable Ventricular Assist Device, or IVAD, in Europe. The IVAD is the only currently approved implantable cardiac assist device that can provide left, right or biventricular support.

### **Results of Operations**

#### **Three months ended June 2003 and 2002**

##### ***Product Sales***

Product sales in the second quarter of 2003 were \$36.2 million compared to \$31.0 million in the second quarter of 2002, an increase of approximately \$5.2 million, or 17%. This increase is primarily attributable to an increase in the number of VAD units sold both domestically and internationally of \$3.3 million, higher sales of graft products of \$0.5 million, and higher sales of blood coagulation testing equipment products of \$1.4 million.

##### ***Gross Profit***

Gross profit was \$21.5 million, representing 59% of product sales, for the second quarter of 2003 compared to \$17.8 million, representing 57% of product sales, for the second quarter of 2002. The increase in gross profit percentage was primarily a result of lower merger related employee retention costs, higher average selling prices for VAD products due principally to customer mix between the two periods and higher sales of higher margin coagulation products, slightly offset by lower average selling prices on skin incision products.

##### ***Selling, General and Administrative***

Selling, general and administrative expenses increased to \$11.2 million, or 31% of product sales, in the second quarter of 2003, from \$9.8 million, or 32% of product sales, in the second quarter of 2002. While selling, general and administrative expenses were generally consistent as a percentage of sales from period to period, the increase in expense dollars was primarily due to higher employee related costs, expenses related to increased marketing efforts and higher insurance costs.

##### ***Research and Development***

Research and development expenses increased to \$6.3 million, or 17% of product sales, in the second quarter of 2003, from \$6.1 million, or 20% of product sales, in the second quarter of 2002. This increase was primarily due to slightly higher spending on certain cardiovascular projects.

##### ***Amortization of Purchased Intangible Assets***

Amortization of identified purchased intangible assets remained consistent from the second quarter of 2002 to the second quarter of 2003 at \$3.1 million. Intangible assets are being amortized over their estimated useful lives of eight to twenty years.

## **Table of Contents**

### ***Merger, Restructuring and Other Costs***

Merger, restructuring and other costs in the second quarter of 2003 were \$0.1 million of reduction in expense compared to \$0.5 million of expense in the second quarter of 2002. Restructuring activities and related expenses were completed in the second quarter of 2003 and the restructuring accrual was reduced to reflect no remaining liability as of the end of the second quarter of 2003. Merger activities and related expenses were completed in the third quarter of 2002.

### ***Interest and Other Income (Expense) - Net***

Interest and other income (expense) net was \$0.6 million in the second quarter of 2003 compared to \$0.9 million in the second quarter of 2002. This decrease is primarily attributable to a decrease in other income (expense) of \$0.1 million resulting from lower foreign currency gains and decrease in interest income of \$0.1 million due to lower interest rates.

### ***Income Taxes***

Our effective income tax expense rate was 39% for the three-month period ended June 28, 2003. For the three-month period ended June 29, 2002, our effective income tax benefit rate was 40%. The effective income tax expense rate for the current fiscal quarter and the effective income tax benefit rate for the prior fiscal quarter differed from the statutory federal income tax rate primarily due to the impact of state taxes.

### **Six months ended June 2003 and 2002**

#### ***Product Sales***

Product sales in the first six months of 2003 were \$72.2 million compared to \$60.7 million in the first six months of 2002, an increase of approximately \$11.5 million, or 19%. This increase is primarily attributable to an increase in the number of VAD units sold of \$7.7 million, higher sales of graft products of \$1.3 million, and higher sales of blood coagulation testing equipment of \$2.6 million.

#### ***Gross Profit***

Gross profit was \$42.7 million, representing 59% of product sales, for the first six months of 2003 compared to \$34.2 million, representing 56% of product sales, for the first six months of 2002. The increase in gross profit percentage was primarily a result of lower merger related employee retention costs, higher average selling prices for VAD products due principally to customer mix between the two periods and higher sales of higher margin coagulation products, slightly offset by lower average selling prices on skin incision products.

#### ***Selling, General and Administrative***

Selling, general and administrative expenses increased to \$21.2 million, or 29% of product sales, in the first six months of 2003, from \$18.6 million, or 31% of product sales, in the first six months of 2002. While selling, general and administrative expenses decreased as a percentage of sales from period to period, the increase in expense dollars was primarily due to higher employee related costs, expenses related to increased marketing efforts and business development activities and increased insurance costs.

#### ***Research and Development***

Research and development expenses decreased to \$12.5 million, or 17% of product sales, in the first six months of 2003, from \$13.0 million, or 21% of product sales, in the first six months of 2002. This decrease was primarily due to lower spending on certain cardiovascular projects, partially offset by slightly higher spending on the development of a new hand-held point of care blood analyzer product.

#### ***Amortization of Purchased Intangible Assets***

Amortization of identified purchased intangible assets remained consistent from the first six months of 2002 to the first six months of 2003 at \$6.2 million. Intangible assets are being amortized over their estimated useful lives of eight to twenty years.



## **Table of Contents**

### ***Merger, Restructuring and Other Costs***

Merger, restructuring and other costs in the second quarter of 2003 were \$0.1 million of reduction in expense compared to \$0.5 million of expense in the second quarter of 2002. Restructuring activities and related expenses were completed in the second quarter of 2003 and the restructuring accrual was reduced to reflect no remaining liability as of the end of the second quarter of 2003. Merger activities and related expenses were completed in the third quarter of 2002.

### ***Interest and Other Income (Expense) - Net***

Interest and other income (expense) net was \$1.2 million in the first six months of 2003 compared to \$0.5 million in the first six months of 2002. Interest expense decreased by \$0.5 million and other income (expense) increased by \$0.5 million from 2002 to 2003 primarily due to the repayment of our subordinated debentures in the first six months of 2002 and the related write-off of unamortized debt issuance costs. These increases were partially offset by a decrease in interest income from 2002 to 2003 due to lower interest rates.

### ***Income Taxes***

Our effective income tax expense rate was 39% for the six-month period ended June 28, 2003. For the six-month period ended June 29, 2002, our effective income tax benefit rate was 40%. The effective income tax expense rate for the current fiscal quarter and the effective income tax benefit rate for the prior fiscal quarter differed from the statutory federal income tax rate primarily due to the impact of state taxes.

### ***Liquidity and Capital Resources***

At June 28, 2003, we had working capital of \$120.0 million compared with \$108.0 million at December 28, 2002. Cash and cash equivalents at June 28, 2003 were \$57.5 million compared to \$42.0 million at December 28, 2002, an increase of \$15.5 million.

During the first six months of 2003, cash provided by operating activities was \$12.8 million. This results from the combination of our net income of \$2.4 million and \$11.0 million of items not affecting second quarter 2003 cash flows, primarily depreciation and amortization expenses, less changes in working capital of \$0.6 million. The change in working capital in the second quarter of 2003 was due principally to a decrease in accounts payable and other accrued liabilities and an increase in prepaid and other assets, partially offset by a decrease in inventory and accounts receivable. Net cash used in operating activities was \$1.0 million in the second quarter of 2002. This resulted from the combination of our net loss of \$2.3 million and \$7.8 million of items not affecting second quarter 2002 cash flows, primarily depreciation and amortization expenses, less changes in working capital of \$6.5 million.

During the first six months of 2003, \$1.6 million of cash was used in our investing activities compared to \$42.2 million of cash provided in the first six months of 2002. During the first six months of 2003, we purchased \$4.4 million in short-term and long-term investments and \$2.8 million of cash was used for capital expenditures. These uses of cash for investing activities were partially offset by sales of short-term and long-term investments of \$5.7 million. Cash provided in the second quarter of 2002 was due to the reclassification of \$45.9 million from restricted cash to retire our subordinated debentures, partially offset by \$3.7 million used for capital expenditures.

During the first six months of 2003, \$4.1 million of cash was provided by financing activities compared to \$44.8 million of cash used in financing activities in the first six months of 2002. Cash provided in the second quarter of 2003 was due to proceeds from the exercise of common stock options and stock purchased under our employee stock purchase plan. Cash used in the second quarter of 2002 was due to \$54.8 million used to retire our subordinated debentures and \$6.0 million used to repurchase our common stock, partially offset by \$15.5 million net proceeds received in a public stock offering and \$0.6 million provided from exercises of common stock options.

We believe that our cash on-hand, short-term available-for-sale investments and expected cash flow from operations will be sufficient to fund our operations and capital requirements for the foreseeable future. We expect that our operating expenses will increase in future periods as we spend more on product manufacturing, sales and marketing and research and development of new product lines.

The impact of inflation on our financial position and results of operations was not significant during the three and six-month periods ended June 28, 2003 and June 29, 2002.

**Table of Contents**

**Critical Accounting Policies**

We have identified certain accounting policies as critical to our business operations and the understanding of our results of operations. The impact and associated risks related to those policies on our business operations is discussed below and in our fiscal 2002 consolidated financial statements filed with the SEC in our annual report on Form 10-K.

In April 2002, the FASB issued SFAS No. 145, ( Rescission of FASB Statements 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections ) which, among other things, changed the presentation of gains and losses on the extinguishment of debt. Any gain or loss on extinguishment of debt that does not meet the criteria in Accounting Principle Board, or APB, Opinion No. 30, Reporting the Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions, shall be included in operating earnings and not presented separately as an extraordinary item. We adopted SFAS No. 145 at the beginning of fiscal year 2003. Upon adoption, we reclassified the extraordinary loss incurred in 2002 of \$0.5 million to interest and other income (expense)-net.

In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure. SFAS No. 148 amends SFAS No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements of the method of accounting for stock-based employee compensation and the effect of the method used on reported results. SFAS No. 148 is effective for fiscal years beginning after December 15, 2002. We adopted the disclosure provisions of SFAS No. 148 at the beginning of fiscal 2003. Currently we are evaluating the impact of the adoption of the use of the fair value based method of accounting for stock-based financial position, results of operations and cash flows.

**Table of Contents**

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE OF MARKET RISK**

**Short-Term and Long-Term Investments**

Our exposure to market risk for changes in interest rates relates to our investment portfolio. The investment portfolio is made up of cash equivalent and marketable security investments in money market funds and debt instruments of government agencies and high quality corporate issuers. All investments are carried at market value and are treated as available-for-sale. All investments mature within two years or less from the date of purchase. The holdings of any one issuer, except government agencies, do not exceed 10% of the portfolio. If interest rates rise, the market value of our investments may decline which could result in a loss if we are forced to sell an investment before the scheduled maturity. We do not utilize derivative financial instruments to manage interest rate risks.

**Foreign Currency Rate Fluctuations**

We conduct business in foreign countries. Our international operations consist primarily of sales and service personnel for our ventricular assist products. The employees report into our U.S. sales and marketing group and are internally reported as part of that group. All assets and liabilities of our non-U.S. operations are translated into U.S. dollars at the period-end exchange rates. The resulting translation adjustments are included in comprehensive income. The period-end translation of the non-functional currency balances (the result of foreign sales, foreign expenses, and intercompany transactions) in our wholly owned subsidiary in the United Kingdom at the period-end exchange rate into the functional currency of our subsidiary results in foreign currency exchange gains and losses. These foreign currency exchange gains and losses are included in interest and other income-net and were not material for the three-month and six-month periods ended June 28, 2003 and June 29, 2002. Currently, we do not expect to be subject to material foreign currency risk with respect to future costs or cash flows from our foreign operations. To date, we have not entered into any significant foreign currency hedging contracts or other derivative financial instruments to hedge the effects of adverse fluctuations in foreign currency exchange, however, we are currently evaluating possible future use of such contracts and instruments.

**ITEM 4. CONTROLS AND PROCEDURES**

An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 28, 2003. Based on that evaluation, our management, including the Chief Executive Officer and Chief Financial Officer, concluded that as of June 28, 2003 the Company's disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. There have been no changes in our internal controls during the fiscal quarter ended June 28, 2003 that have materially affected or are reasonably likely to materially affect the Company's internal control over financial reporting.

Our management, including the Chief Executive Officer and the Chief Financial Officer, do not expect that the disclosure controls and procedures or internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been or will be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all future conditions; over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

We intend to review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis and to improve our controls and procedures over time and to correct any deficiencies that we may discover in the future. Our senior management have timely access to all material financial and non-financial information concerning our business. While we believe the present design of our disclosure controls and procedures is effective, future events affecting our business may cause us to significantly modify our disclosure controls and procedures.

**Table of Contents****PART II. OTHER INFORMATION****ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY SHAREHOLDERS**

The annual meeting of Shareholders was held on May 30, 2003. The following items were voted upon and approved at the meeting:

To elect directors to serve for the ensuing year until their successors are elected.

	Number of Votes	
	For	Withheld
Howard E. Chase	50,241,346	2,019,890
J. Daniel Cole	50,241,380	2,019,856
D. Keith Grossman	50,241,133	2,020,103
J. Donald Hill	50,241,380	2,019,856
William M. Hitchcock	50,241,380	2,019,856
George W. Holbrook Jr.	50,241,247	2,019,989
Theo Melas-Kyriazi	50,206,388	2,054,898
Daniel M. Mulvena	50,241,413	2,019,823

To approve the amendment to the Company's 1997 Stock Option Plan as described in the Proxy Statement.

Number of Votes			
For	Against	Abstain	Not Voted
31,549,871	10,010,465	337,810	10,363,090

To approve the amendment to the Company's 1996 Nonemployee Directors Stock Option Plan as described in the Proxy Statement.

Number of Votes			
For	Against	Abstain	Not Voted
35,382,072	6,515,772	341,074	10,022,318

**ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K**

(a) Exhibits:

31.1 Section 302 Certifications of Chief Executive Officer and Chief Financial Officer

32.1 Section 906 Certifications of Chief Executive Officer and Chief Financial Officer

(b) Reports on Form 8-K:

On April 22, 2003, the Company filed a Current Report on Form 8-K, reporting under Items 7, 9 and 12, announcing the company's results for the fiscal quarter ended March 29, 2003.



**Table of Contents**

**SIGNATURES**

In accordance with the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THORATEC CORPORATION

Date: August 8, 2003

/s/ D. Keith Grossman  
\_\_\_\_\_

D. Keith Grossman,  
Chief Executive Officer

Date: August 8, 2003

/s/ M. Wayne Boylston  
\_\_\_\_\_

M. Wayne Boylston,  
Senior Vice President,  
Chief Financial Officer and Secretary  
(Principal Financial and Accounting Officer)

**Table of Contents**

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
31.1	Section 302 Certifications of Chief Executive Officer and Chief Financial Officer
32.1	Section 906 Certifications of Chief Executive Officer and Chief Financial Officer